have heard a lot about companies in

have heard a lot about companies involved in finding a hair loss cure via PGD2 inhibition, PGE2 increase, wounding, hair cloning, hair multiplication, hair regeneration, dermal papilla cell manipulation, fat cell manipulation, newer anti-androgen development and more. Samumed seems to be the most likely company in the world at tackling hair loss via the Wnt/Beta-Catenin signaling pathway and therefore it is worth following the company even if it keeps releasing information in bits and pieces.

As far as the latest press release that I mentioned at the start of the post goes, the key sentence regarding Phase II clinical trials for the company’s SM04554 topical solution is that the product:

“Showed statistically significant increases for both objective outcome measures: non-vellus hair count (a primary outcome measures) and hair density (a secondary outcome measures), using the pre-specified statistical model.”

I am not overly excited about reading the above, as “statistically significant” could just mean yet another Minoxidil or Propecia (or even Bimatoprost — see Results) type treatment. However, with no evidence of significant side effects, SM04554 could be a great product if it enhances the effects of existing treatments (as opposed to different treatments cancelling each other’s benefits out and impacting the same hair positively, even if working via totally different mechanisms).

The most encouraging thing I read was that in in vivo animal models, SM04554 has shown to generate new hair follicles. This is a very rare outcome for any hair loss medication or treatment, as in most cases existing hair is made stronger and recently miniaturized hair is brought back to life. We are long overdue for hair growth success stories in animal models being replicated in homo sapiens.

結果 (中文) 1:

听说过很多公司参与寻找脱发治愈通过 PGD2 抑制、 PGE2 增加、 伤人、 头发克隆、 头发乘法、 头发再生，毛乳头细胞操作，脂肪细胞操作、 更新的反雄发展和更多。Samumed 似乎是最有可能在世界上解决脱发通过 Wnt/β-Catenin 信号转导通路公司，因此它是值得遵循公司，即使它不断释放中零碎的信息。最新的新闻稿，我刚才所提及的邮报 》 开始走得，关键的一句关于第二阶段临床试验公司的 SM04554 外用溶液是一样的产品:"显示有统计学意义，提高这两个客观的结果措施: 非毳毛计数 (主要指标) 和头发密度 (二级指标)，使用预先指定的统计模型。"不过分高兴关于读了以上，作为"统计学"仅仅意味着另一个米诺地尔或保法止 (或甚至比马前列素 — — 看到结果) 键入治疗。然而，没有明显的证据，SM04554 可能是副作用的一个伟大的产品如果它提高的影响，现有的治疗方法 (而不是副作用的不同的治疗方法抵消彼此的利益和相同的头发都产生积极影响，即使工作通过完全不同的机制)。The most encouraging thing I read was that in in vivo animal models, SM04554 has shown to generate new hair follicles. This is a very rare outcome for any hair loss medication or treatment, as in most cases existing hair is made stronger and recently miniaturized hair is brought back to life. We are long overdue for hair growth success stories in animal models being replicated in homo sapiens.

結果 (中文) 3:

听说过很多关于参与找到脱发治疗通过抑制前列腺素PGD2，公司增加，伤人，克隆头发，头发乘法，毛发再生，毛乳头细胞操纵，操纵新的脂肪细胞，抗雄激素的开发和更。samumed似乎是世界上最有可能的公司在解决脱发通过Wnt/β-catenin信号通路，因此值得在公司即使是保持在零碎的信息发布。

就最新的新闻稿，我提到在最开始就，关于公司的sm04554外用溶液II期临床试验的关键句是：产品

”表现出统计上的显着增加的客观观察指标：非毳毛计数（主要终点）和头发密度（次要疗效指标），使用预先指定的统计模型。”

我是不是看了上面的过度兴奋，“统计学”就意味着另一种米诺地尔和保法止（甚至比马前列素-见结果）型的治疗。然而，无明显副作用，sm04554如果能提高现有的治疗效果是一个伟大的产品（与不同处理消除彼此的利益和影响同样的头发正，即使工作通过完全不同的机制）。

最鼓舞人心的事情是，我读了动物模型体内，sm04554显示生成新毛囊。这是一个非常罕见的结果，对于任何脱发药物治疗或治疗，因为在大多数情况下，现有的头发是做强和最近的小型化的头发被带回到生活。我们期待已久的头发生长成功的故事在智人复制动物模型。